Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2019 | Role of BM on clinical outcomes in mUC patients

Bone metastases (BM) are a major cause for morbidity in metastatic urothelial cancer (mUC) and thus it is important to evaluate the differences in clinical outcomes in mUC patients with BM and without BM. Srikala Sridhar, MD, FRCPC, of the Princess Margaret Cancer Centre, Toronto, ON, discusses results from a retrospective study investigating the impact of BM on the responses to chemotherapy in mUC patients. This video was recorded at the 2019 Genitourinary Cancers Symposium, held in San Francisco, CA.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.